Literature DB >> 27641814

Antibiotic use and microbiome function.

Manuel Ferrer1, Celia Méndez-García2, David Rojo3, Coral Barbas3, Andrés Moya4.   

Abstract

Our microbiome should be understood as one of the most complex components of the human body. The use of β-lactam antibiotics is one of the microbiome covariates that influence its composition. The extent to which our microbiota changes after an antibiotic intervention depends not only on the chemical nature of the antibiotic or cocktail of antibiotics used to treat specific infections, but also on the type of administration, duration and dose, as well as the level of resistance that each microbiota develops. We have begun to appreciate that not all bacteria within our microbiota are vulnerable or reactive to different antibiotic interventions, and that their influence on both microbial composition and metabolism may differ. Antibiotics are being used worldwide on a huge scale and the prescription of antibiotics is continuing to rise; however, their effects on our microbiota have been reported for only a limited number of them. This article presents a critical review of the antibiotics or antibiotic cocktails whose use in humans has been linked to changes in the composition of our microbial communities, with a particular focus on the gut, oral, respiratory, skin and vaginal microbiota, and on their molecular agents (genes, proteins and metabolites). We review the state of the art as of June 2016, and cover a total of circa 68 different antibiotics. The data herein are the first to compile information about the bacteria, fungi, archaea and viruses most influenced by the main antibiotic treatments prescribed nowadays.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ampicillin (PubChem CID: 6249); Antibiotics; Cephalosporin (PubChem CID: 25058126); Ciprofloxacin (PubChem CID: 2764); Clindamycin (PubChem CID: 29029); Erythromycin (PubChem CID: 12560); Gentamicin (PubChem CID: 3467); Metronidazole (PubChem CID: 4173); Microbiome; Microbiota; OMICS; Streptomycin (PubChem CID: 19649); Tetracycline (PubChem CID: 54675776); Vancomycin (PubChem CID: 14969)

Mesh:

Substances:

Year:  2016        PMID: 27641814     DOI: 10.1016/j.bcp.2016.09.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  68 in total

1.  Intracellular Accumulation of Staphylopine Can Sensitize Staphylococcus aureus to Host-Imposed Zinc Starvation by Chelation-Independent Toxicity.

Authors:  Kyle P Grim; Jana N Radin; Paola K Párraga Solórzano; Jacqueline R Morey; Katie A Frye; Katherine Ganio; Stephanie L Neville; Christopher A McDevitt; Thomas E Kehl-Fie
Journal:  J Bacteriol       Date:  2020-04-09       Impact factor: 3.490

2.  Effects of a perioperative antibiotic and veterinary probiotic on fecal dysbiosis index in dogs.

Authors:  Brittany Lucchetti; Selena L Lane; Amie Koenig; Jennifer Good; Jan S Suchodolski; Benjamin M Brainard
Journal:  Can Vet J       Date:  2021-03       Impact factor: 1.008

Review 3.  Gastrointestinal tract microbiota modifications in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Anna-Maria Hoffmann-Vold
Journal:  Eur J Rheumatol       Date:  2019-12-19

Review 4.  Metabolomic applications in radiation biodosimetry: exploring radiation effects through small molecules.

Authors:  Evan L Pannkuk; Albert J Fornace; Evagelia C Laiakis
Journal:  Int J Radiat Biol       Date:  2017-01-12       Impact factor: 2.694

Review 5.  Early-life adversity, epigenetics, and visceral hypersensitivity.

Authors:  S Liu; S I Hagiwara; A Bhargava
Journal:  Neurogastroenterol Motil       Date:  2017-09       Impact factor: 3.598

Review 6.  The Human Microbiota and Asthma.

Authors:  Aaron Ver Heul; Joseph Planer; Andrew L Kau
Journal:  Clin Rev Allergy Immunol       Date:  2019-12       Impact factor: 8.667

Review 7.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 8.  COPD and the gut-lung axis: the therapeutic potential of fibre.

Authors:  Annalicia Vaughan; Zoe A Frazer; Philip M Hansbro; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 9.  The oral microbiota - a mechanistic role for systemic diseases.

Authors:  G Jia; A Zhi; P F H Lai; G Wang; Y Xia; Z Xiong; H Zhang; N Che; L Ai
Journal:  Br Dent J       Date:  2018-03-23       Impact factor: 1.626

10.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.